What Evopoint Biosciences does

Evopoint Biosciences (苏州信诺维医药科技股份有限公司) is a privately held, clinical-stage biopharmaceutical company founded in 2018 in Suzhou, China, with additional offices in Shanghai, Beijing, and Waltham, Massachusetts. The company develops innovative therapeutics for major unmet medical needs across three verticals: precision oncology (solid tumors and hematologic malignancies), multidrug-resistant bacterial infections, and immune-mediated kidney diseases. Its pipeline of seven clinical-stage and more than ten preclinical-stage programs is anchored by three proprietary technology platforms: a Small Molecule Drug Discovery Platform (epigenetics, synthetic lethality, anti-infectives), the eMAB Complex Antibody Drug Development Platform for next-generation ADCs, bispecifics, and T-cell engagers, and the eGLUE Targeted Protein Degradation Platform for molecular glue and heterobifunctional degraders.

The company's lead clinical assets include XNW4107 (fonobactam/福诺巴坦), a novel DBO β-lactamase inhibitor combined with imipenem/cilastatin for carbapenem-resistant gram-negative infections whose NDA has been accepted following Phase III success (REITAB-2); XNW5004 (igermetostat), an EZH2 inhibitor with CDE Breakthrough Therapy Designation in PTCL and FL and Phase III data in mCRPC; XNW27011, a CLDN18.2-targeting ADC licensed ex-Greater China to Astellas in a deal worth $130M upfront plus up to $1.34B in milestones; XNW28012, a Tissue Factor ADC for pancreatic cancer with both CDE BTD and FDA Fast Track; XNW1011 (civorebrutinib/希布替尼), a covalent reversible BTK inhibitor partnered with Everest Medicines and sublicensed to Travere Therapeutics; and the earlier-stage XNW29016 (PARG inhibitor) and XNW34017 (first-in-class AURKA-MYC protein degrader). Multiple assets have secured both CDE Breakthrough Therapy Designation and FDA Fast Track Designation.

Evopoint monetizes its pipeline primarily through out-licensing and partnerships with global pharmaceutical companies, receiving upfront payments, development/registration/commercial milestones, and tiered royalties, rather than through direct product commercialization. Its reported total announced deal value exceeds $2 billion across the Astellas, Everest, and Travere transactions. The company is backed by Apricot Capital and Advantech Capital (New Horizon Capital) and is led by veterans from CICC, Pfizer, Wyeth, Bayer, Amgen, Merck Serono, WuXi AppTec, and Pharmaron. It operates a 40,000 sqm manufacturing and operations base in Suzhou Industrial Park.

Name

Evopoint Biosciences

Legal name

苏州信诺维医药科技股份有限公司

Website

https://evopointbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Short description

Evopoint Biosciences is a private Suzhou-based clinical-stage biotech developing small-molecule, ADC, and protein-degrader therapies for oncology, MDR bacterial infections, and kidney disease, monetizing its pipeline through out-licensing deals with global pharma partners.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody-drug conjugates
• Targeted protein degradation
• Oncology drug development
• Multidrug-resistant antibiotics
• Biopharmaceutical licensing

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Licensing and Milestone Payments: Evopoint receives upfront payments, development milestones, registration milestones, and commercial milestones from licensing partners. For XNW27011 with Astellas: $130M upfront + $70M near-term + up to $1.34B in development/registration/commercial milestones + tiered royalties on net sales.
2. Revenue Sharing from Partner Agreements: Evopoint receives a percentage of revenue sharing from its partner Everest Medicines' licensing deals, including the Travere Therapeutics agreement for XNW1011 where Evopoint receives a certain percentage of revenue sharing.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Evopoint Biosciences is a platform-based biopharmaceutical company that discovers and develops innovative drug candidates across precision oncology and multidrug-resistant infectious diseases, using three proprietary technology platforms (small molecule drug discovery, complex antibody/eMAB, and targeted protein degradation/eGLUE). The company advances its pipeline through clinical development and out-licenses proprietary candidates to global pharmaceutical partners for further development, commercialization, and territorial rights, while also operating its own manufacturing base.

Product overview

Evopoint Biosciences is a platform-based innovative pharmaceutical company with three core technology platforms: Small Molecule Drug Discovery Platform, Novel Antibody Discovery Platform (eMAB), and Targeted Protein Degradation Platform (eGLUE). The company's pipeline consists of 7 clinical-stage products and 10+ preclinical programs focused on precision oncology and multidrug-resistant infections. Key products include: XNW4107 (β-lactamase inhibitor, NDA stage), XNW5004 (EZH2 inhibitor, Phase III), XNW27011 (CLDN18.2 ADC, Phase III, licensed to Astellas), XNW28012 (TF ADC, Phase III), XNW1011 (BTK inhibitor, Phase II), XNW29016 (PARG inhibitor, Phase I), and XNW34017 (AURKA-MYC degrader, IND-enabling). The company has established a 40,000 sqm manufacturing base for drug production and has achieved licensing deals exceeding $2 billion in total value.

Differentiator

Problem solved

Functional benefit

Products and services

• XNW4107 (Fonobactam, 福诺巴坦) — IMI/FUN combination (imipenem/cilastatin-fonobactam, 亚胺西福) A first-in-class novel diazabicyclooctane (DBO) beta-lactamase inhibitor that comprehensively covers CRAB, CRE, and CRPA pathogens (Class A, C, and D serine-based beta-lactamases), combined with imipenem/cilastatin to treat HABP/VABP and other infections caused by carbapenem-resistant gram-negative bacteria. Received FDA Fast Track Designation and QIDP certification.
• XNW5004 (Igermetostat) A best-in-class selective EZH2 inhibitor (small molecule) developed for peripheral T-cell lymphoma (PTCL), follicular lymphoma (FL), and metastatic castration-resistant prostate cancer (mCRPC). Received CDE Breakthrough Therapy Designation for r/r PTCL and r/r FL (EZH2 wild-type).
• XNW27011 (CLDN18.2 ADC) A next-generation antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2) with a proprietary topoisomerase I inhibitor payload and cleavable linker (DAR 8), developed for CLDN18.2-positive solid tumors including gastric, gastroesophageal, and pancreatic cancers; licensed to Astellas for global development and commercialization excluding Greater China.
• XNW28012 (TF ADC) A novel antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with a highly potent DNA topoisomerase I inhibitor conjugated via a stable cleavable linker, developed for metastatic pancreatic cancer and other solid tumors; received both CDE Breakthrough Therapy Designation and FDA Fast Track Designation.
• XNW1011 (Civorebrutinib, 希布替尼 / EVER001) A next-generation covalent reversible BTK inhibitor developed for B-cell-related hematological malignancies and immune-mediated kidney diseases including primary membranous nephropathy (PMN), IgA nephropathy, MCD, FSGS, and lupus nephritis; co-licensed with SinoMab (autoimmune) and Everest Medicines (renal), with Everest sublicensing to Travere Therapeutics outside Greater China and certain Southeast Asian countries.
• XNW29016 A first-in-class PARG (poly ADP-ribose glycohydrolase) inhibitor being developed for advanced solid tumors; currently in Phase I clinical study.
• XNW34017 (AURKA-MYC degrader) A first-in-class, orally bioavailable, brain-penetrant bifunctional AURKA-MYC protein degrader developed via Evopoint's eGLUE TPD platform; the world's first degrader capable of efficiently degrading both AURKA and Myc family proteins (c-Myc, L-Myc, N-Myc), currently in IND-enabling studies for Myc-driven cancers.

Quantifiable outcome

• XNW27011 CLDN18.2 ADC licensed to Astellas for up to $1.34 billion total deal value
• +4 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• Travere TherapeuticscoreStrategic or Co-development Partner · 2 June 2026Travere licensed XNW1011/EVER001 (civorebrutinib) from Everest Medicines for all markets outside China and certain Southeast Asian countries for immune-mediated kidney diseases, with $112.5M upfront + up to $1.03B in milestones + tiered royalties. Evopoint receives revenue sharing.
• Astellas Pharma Inc. (安斯泰来)flagshipStrategic or Co-development Partner · 30 May 2025Exclusive license agreement granting Astellas exclusive rights to develop and commercialize XNW27011 (CLDN18.2-targeting ADC) globally excluding mainland China, Hong Kong, Macau, and Taiwan. Evopoint receives $130M upfront + $70M near-term payments + up to $1.34B in development, registration, and commercial milestones + tiered royalties on net sales.
• Everest Medicines (云顶新耀)coreStrategic or Co-development Partner · 1 September 2021Global exclusive collaboration agreement for XNW1011 (BTK inhibitor) in renal disease field. Everest Medicines sublicensed to Travere Therapeutics for all markets outside China and certain Southeast Asian countries, receiving $112.5M upfront + up to $1.03B in milestones. Evopoint receives revenue sharing percentage.
• SinoMab Bioscience Limited (中国抗体)coreStrategic or Co-development Partner · 1 September 2021Co-licensed XNW1011 technology for autoimmune disease indications to SinoMab Bioscience. Joint development partnership with Everest Medicines for global renal disease rights.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Junshi Biosciences: China-headquartered biotech with both innovative small molecules and biologics, including ADC programs, and major cross-border licensing deals (Coherus, Lilly). Comparable in modality breadth, China origin, and partnership-driven commercialization.
• Hutchmed: Hong Kong/China-headquartered oncology-focused biotech with multiple global out-licensing deals (AstraZeneca, Takeda, Eli Lilly) and NDA-stage assets. Closely comparable to Evopoint's discovery-plus-licensing model and oncology focus.
• Innovent Biologics: China-based biotech with a strong biologics and ADC pipeline plus major global pharma licensing deals (e.g., Lilly partnership on sintilimab). Comparable to Evopoint in modality mix (biologics + small molecules), China origin, and out-licensing business model.
• Akeso: China-based biotech with a leading bispecific antibody pipeline (e.g., ivonescimab, cadonilimab) and large multi-program licensing deals (Summit Therapeutics). Highly comparable to Evopoint's eMAB antibody platform and global licensing playbook.
• Hansoh Pharmaceutical: Chinese innovative pharma with oncology and infectious disease pipelines that has generated multiple global out-licensing deals. Comparable to Evopoint in therapeutic-area focus (oncology + anti-infectives) and licensing-driven global expansion.
• BeiGene: China-born biotech with global commercial footprint, broad oncology pipeline, and significant licensing arrangements. Comparable to Evopoint as a Chinese oncology innovator pursuing multi-modality (small molecule and biologic) drug development with global pharma partnerships.
• Cstone Pharmaceuticals: China-based oncology biotech that has used global licensing deals (e.g., Pfizer partnership for sugemalimab) to advance its pipeline. Similar to Evopoint as a Chinese oncology innovator leveraging pharma partnerships to fund and globalize development.

Emerging players

• Cullgen: US/China-based TPD-focused biotech developing targeted protein degraders, including against oncogenic targets. Directly comparable to Evopoint's eGLUE TPD platform and emerging degrader programs such as XNW34017.

Broad incumbents

• AstraZeneca: Global oncology leader with significant ADC platform investments (via Daiichi Sankyo collaboration) and active in-licensing of China-developed oncology assets. Comparable as a counterparty/competitor dynamic and as a benchmark for global pharma demand for innovative oncology assets like Evopoint's.
• Daiichi Sankyo: Global pharma that pioneered topoisomerase-I-inhibitor ADC payloads (DXd platform, Enhertu) and entered multi-billion ADC partnerships with AstraZeneca. Comparable to Evopoint at the platform-technology level, given Evopoint's topo-I payload and linker for XNW27011 and XNW28012.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evopoint Biosciences